<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002972</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-08956</org_study_id>
    <secondary_id>EORTC-08956</secondary_id>
    <nct_id>NCT00002972</nct_id>
  </id_info>
  <brief_title>Paclitaxel in Treating Patients With Lung Cancer</brief_title>
  <official_title>Phase II Study on TAXOL in Bronchioalveolar Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients who&#xD;
      have unresectable stage IIIB, stage IV or recurrent lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the therapeutic activity of paclitaxel in patients with bronchoalveolar carcinoma&#xD;
           (BAC).&#xD;
&#xD;
        -  Assess the duration of response in patients presenting with an objective response.&#xD;
&#xD;
        -  Characterize the acute side effects of paclitaxel in patients with BAC.&#xD;
&#xD;
        -  Assess the role of some biological parameters in the natural history and the response to&#xD;
           therapy of BAC; evaluate the expression of Ki67, p53, and K-ras mutation.&#xD;
&#xD;
      OUTLINE: This is an open label, nonrandomized, multicenter study.&#xD;
&#xD;
      Paclitaxel is administered every 3 weeks as a 3 hour continuous infusion in dextrose or&#xD;
      normal saline. Patients are treated for a minimum of 2 cycles unless serious toxicity or&#xD;
      complication occur.&#xD;
&#xD;
      Disease is assessed every 6 weeks until documented progression; treatment side effects are&#xD;
      assessed separately for each cycle of therapy. Treatment is given up to a maximum of 6 cycles&#xD;
      of therapy or until disease progression, unacceptable toxicity, or patient refusal occurs.&#xD;
&#xD;
      PROJECTED ACCRUAL: 16 or 25 patients will be accrued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1997</start_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven bronchoalveolar carcinoma (BAC) based on these criteria:&#xD;
&#xD;
               -  Absence of primary adenocarcinoma elsewhere&#xD;
&#xD;
               -  Absence of a demonstrable central bronchogenic origin&#xD;
&#xD;
               -  A peripheral location in the lung parenchyma&#xD;
&#xD;
               -  Intact interstitial framework of the lung&#xD;
&#xD;
               -  A histological appearance setting it apart from other tumors, with a&#xD;
                  characteristic pattern of growth: cuboidal or cylindrical cells lining up the&#xD;
                  alveolar septa with preservation of basic pulmonary architecture&#xD;
&#xD;
          -  Must be unresectable Stage IIIB, IV, or recurrent BAC&#xD;
&#xD;
          -  Evidence of multinodular lesions involving the lungs bilaterally or unilaterally (in&#xD;
             the latter the lesions must involve more than one lobe)&#xD;
&#xD;
          -  At least one target lesion bidimensionally measurable that has not undergone prior&#xD;
             irradiation&#xD;
&#xD;
          -  No CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 75 (inclusive)&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  ANC at least 1,500/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2 times upper limit of normal&#xD;
&#xD;
          -  SGOT, SGPT, and alkaline phosphatase less than 2 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 1.5 times upper limit of normal&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of ischemic or congestive heart disease&#xD;
&#xD;
          -  No arrhythmia requiring chronic cardiopulmonary medications&#xD;
&#xD;
          -  No history of clinically or electrographically documented myocardial infarction&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No preexisting motor or other serious sensory neurotoxicity&#xD;
&#xD;
          -  No active or prior second primary cancer except basal cell carcinoma of the skin or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No clinical evidence of uncontrolled infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test 72 hours prior to start of study medication&#xD;
&#xD;
          -  Adequate contraception required of all fertile patients&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since radiotherapy&#xD;
&#xD;
          -  Must have at least one bidimensional lesion outside the irradiated fields&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Fully recovered from any prior major surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giorgio Scagliotti, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Azienda Ospedale S. Luigi at University of Torino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de la Citadelle</name>
      <address>
        <city>Liege (Luik)</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Thomayers' Hospital</name>
      <address>
        <city>Krhanice</city>
        <zip>257 42</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik und Strahlenklinik - Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedale S. Luigi - Universita Di Torino</name>
      <address>
        <city>Orbassano, (Torino)</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1001HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Scagliotti GV, Smit E, Bosquee L, O'Brien M, Ardizzoni A, Zatloukal P, Eberhardt W, Smid-Geirnaerdt M, de Bruin HG, Dussenne S, Legrand C, Giaccone G; European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group (LCG). A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer. 2005 Oct;50(1):91-6. doi: 10.1016/j.lungcan.2005.05.012.</citation>
    <PMID>16019107</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 16, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2003</study_first_posted>
  <last_update_submitted>June 29, 2012</last_update_submitted>
  <last_update_submitted_qc>June 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

